Key takeaways
- BPC-157 is a 15-amino-acid peptide from a gastric protein; TB-500 is based on the actin-binding region of thymosin beta-4.
- BPC-157 research centers on angiogenesis, NO signaling and gut-barrier models; TB-500 on actin dynamics and cell migration.
- They are studied together because their mechanisms are complementary.
- The evidence base for both is preclinical.
BPC-157 and TB-500 are two of the most widely referenced peptides in preclinical tissue-remodeling research. They are often mentioned together, but they come from different proteins, have different structures and are studied through different mechanisms.
Side-by-side comparison
| BPC-157 | TB-500 | |
|---|---|---|
| Source protein | Body protection compound (human gastric juice) | Thymosin beta-4 (Tβ4) |
| Size | 15 amino acids | Short fragment of a 43-amino-acid protein |
| Mechanism of interest | Angiogenesis, nitric-oxide signaling, growth-factor receptors | G-actin binding, actin polymerization, cell migration |
| Typical models | Gastrointestinal, tendon, ligament and muscle injury | Wound, cardiac, corneal and dermal |
| Notable property | Stable in gastric juice | Abundant in platelets and wound fluid |
BPC-157
BPC-157 is a synthetic peptide corresponding to a partial sequence of “body protection compound”, a protein first described in human gastric juice. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Published preclinical work has examined it in tendon, ligament, muscle and gastrointestinal injury models, with mechanistic studies looking at angiogenesis, nitric-oxide signaling and growth-factor receptor expression. Its unusual stability in gastric juice made it a frequent subject of gastrointestinal research.
TB-500
TB-500 is a synthetic research peptide modeled on the actin-binding region of thymosin beta-4, a 43-amino-acid protein present in most nucleated cells. Tβ4 sequesters G-actin and regulates actin polymerization, the machinery behind cell shape and movement. Research focuses on cell migration, angiogenesis, wound-closure and tissue-remodeling models, plus anti-fibrotic and anti-inflammatory signaling in cardiac, corneal and dermal studies.
Because the two peptides act through different pathways, growth-factor and vascular signaling for BPC-157 and cytoskeletal signaling for TB-500, researchers sometimes examine them in the same protocol to study complementary mechanisms.
Single compounds and blends
Combined preparations are available for multi-pathway studies, and single compounds make useful controls.
What the evidence is, and isn’t
The research base for both compounds is predominantly preclinical: cell-culture and animal studies. Those findings do not establish safety or efficacy in people, and neither compound is approved as a drug.
Confirm the identity and purity of your material with its batch-matched COA, and browse related compounds in Tissue & Inflammatory Pathway Research and Research Blends.
All After Hours Labs products are sold strictly for qualified in-vitro laboratory research. They are not for human or veterinary use, and nothing in this article is medical advice or a recommendation for use in people or animals.
